0R15 8520.0 0.0% 0R1E 8203.0 0.0% 0M69 21090.0 67.5139% 0R2V 226.02 9878.8079% 0QYR None None% 0QYP 412.97 -2.8306% 0RUK 2652.0 -9.2402% 0RYA 1554.0 -0.7029% 0RIH 174.55 -1.3563% 0RIH 165.15 -5.3853% 0R1O 198.5 9800.2494% 0R1O None None% 0QFP None None% 0M2Z 267.777 -0.1763% 0VSO 32.05 -9.9846% 0R1I None None% 0QZI 559.0 0.7207% 0QZ0 220.0 0.0% 0NZF None None% 0YXG 165.7358 2.7149%

Genus PLC

Healthcare GB GNS

1644.0GBP
-42.0(2.49%)

Last update at 2024-11-21T16:35:00Z

Day Range

1644.001714.00
LowHigh

52 Week Range

1836.003186.41
LowHigh

Fundamentals

  • Previous Close 1686.00
  • Market Cap1434.18M
  • Volume67225
  • P/E Ratio42.59
  • Dividend Yield1.47%
  • EBITDA86.90M
  • Revenue TTM689.70M
  • Revenue Per Share TTM10.52
  • Gross Profit TTM 260.60M
  • Diluted EPS TTM0.51

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax 39.40M 48.40M 55.80M 51.50M 9.90M
Minority interest 1.50M 4.20M -1.50000M -1.00000M -1.30000M
Net income 33.30M 40.90M 47.30M 40.50M 7.80M
Selling general administrative 93.10M 85.50M 88.70M 76.10M 68.00M
Selling and marketing expenses - - - - -
Gross profit 239.30M 215.20M 216.80M 221.80M 164.50M
Reconciled depreciation 43.60M 39.00M 35.10M 37.60M 27.50M
Ebit 51.00M 49.40M 47.70M 47.60M 14.20M
Ebitda 94.60M 93.10M 95.40M 94.00M 41.70M
Depreciation and amortization 43.60M 43.70M 47.70M 46.40M 27.50M
Non operating income net other - - - - -
Operating income 40.50M 49.40M 47.70M 47.60M 14.20M
Other operating expenses 649.20M 542.40M 523.30M 484.60M 458.00M
Interest expense 14.30M 5.70M 4.50M 4.90M 4.30M
Tax provision 7.60M 11.70M 9.00M 10.60M 3.20M
Interest income 1.10M 0.40M 0.40M 0.30M 0.20M
Net interest income -14.30000M -6.20000M -5.00000M -5.00000M -4.50000M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 16.60M 11.70M 9.00M 10.60M 3.20M
Total revenue 689.70M 593.40M 574.30M 551.40M 488.50M
Total operating expenses -649.20000M 164.20M 165.80M 155.00M 134.00M
Cost of revenue 450.40M 378.20M 357.50M 329.60M 324.00M
Total other income expense net -1.10000M -1.00000M 8.10M 3.90M -4.30000M
Discontinued operations - - - - -
Net income from continuing ops 39.40M 48.40M 55.80M 40.90M 6.70M
Net income applicable to common shares 33.30M 40.90M 47.30M 40.50M 7.80M
Preferred stock and other adjustments - - - - -
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Total assets 1007.50M 1017.90M 851.00M 868.70M 824.10M
Intangible assets 66.20M 72.00M 56.30M 76.20M 80.10M
Earning assets - - - - -
Other current assets 1.50M 134.70M 109.10M 39.80M 40.10M
Total liab 440.30M 445.80M 354.40M 360.90M 321.80M
Total stockholder equity 569.40M 572.80M 493.00M 503.20M 498.10M
Deferred long term liab - - - - -
Other current liab 98.20M 98.10M 1.60M 7.50M 2.00M
Common stock 6.60M 6.60M 6.60M 6.50M 6.50M
Capital stock 6.60M 6.60M 6.60M 6.50M 6.50M
Retained earnings 360.60M 340.60M 320.40M 294.00M 282.20M
Other liab 75.20M 87.90M 83.20M 106.00M 106.50M
Good will 107.80M 111.00M 101.50M 105.60M 106.30M
Other assets 347.80M 354.60M 289.70M 315.60M 291.00M
Cash 36.30M 38.80M 46.00M 41.30M 30.50M
Cash and equivalents - - - - -
Total current liabilities 147.20M 151.30M 142.50M 130.20M 104.20M
Current deferred revenue - - 7.70M 8.50M 10.20M
Net debt 195.80M 185.00M 105.60M 102.60M 79.60M
Short term debt 14.20M 17.20M 22.90M 19.20M 4.30M
Short long term debt 4.20M 7.10M 13.90M 9.20M 2.10M
Short long term debt total 232.10M 223.80M 151.60M 143.90M 110.10M
Other stockholder equity 202.20M 225.60M 166.00M 202.70M 209.40M
Property plant equipment 164.40M 171.40M 123.00M 117.90M 86.00M
Total current assets 259.00M 257.50M 231.70M 223.80M 209.20M
Long term investments - - - - 31.00M
Net tangible assets 400.90M 395.50M 340.30M 327.00M 302.00M
Short term investments - - - - -
Net receivables 91.50M 101.00M 102.20M 65.50M 62.50M
Long term debt 196.00M 182.10M 109.40M 103.60M 101.90M
Inventory 85.10M 84.00M 76.60M 77.20M 76.10M
Accounts payable 34.80M 36.00M 110.30M 95.00M 87.70M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - -91.90000M -72.10000M
Additional paid in capital - - - - -
Common stock total equity - - 6.60M 6.50M 6.50M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - -0.10000M -0.10000M -0.10000M
Accumulated amortization - - - - -
Non currrent assets other 393.60M 395.90M 330.50M 341.50M 339.00M
Deferred long term asset charges - - - - -
Non current assets total 748.50M 760.40M 619.30M 644.90M 614.90M
Capital lease obligations 31.90M 34.60M 28.30M 31.10M 6.10M
Long term debt total - - - - -
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -30.90000M -67.20000M -3.30000M 1.60M 2.70M
Change to liabilities 6.60M 2.20M 17.90M 12.00M 4.70M
Total cashflows from investing activities -30.90000M -67.20000M -46.70000M -30.70000M -46.10000M
Net borrowings 4.00M 43.50M 7.30M -4.90000M -36.10000M
Total cash from financing activities -18.20000M 21.90M -14.20000M -23.10000M 13.60M
Change to operating activities - - - - 1.50M
Net income 31.80M 36.70M 46.80M 40.90M 6.70M
Change in cash -2.50000M -7.20000M 4.70M 10.80M 1.40M
Begin period cash flow 38.80M 46.00M 41.30M 30.50M 29.10M
End period cash flow 36.30M 38.80M 46.00M 41.30M 30.50M
Total cash from operating activities 50.40M 34.30M 67.50M 65.80M 33.40M
Issuance of capital stock 0.00000M 0.00000M 0.10M 0.10M 66.50M
Depreciation 43.60M 39.00M 35.10M 37.60M 27.50M
Other cashflows from investing activities 0.70M 3.20M 3.70M 3.70M 3.40M
Dividends paid 21.00M 20.90M 19.50M 18.30M 16.80M
Change to inventory -9.60000M -6.10000M -1.30000M 0.10M -3.20000M
Change to account receivables -9.30000M -18.50000M -11.00000M -8.80000M -6.60000M
Sale purchase of stock - - 0.10M 0.10M 66.50M
Other cashflows from financing activities 114.50M 126.70M 181.30M 68.90M 102.80M
Change to netincome -15.30000M -24.10000M -21.40000M -15.80000M 4.00M
Capital expenditures 35.20M 50.90M 33.80M 35.40M 28.30M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -12.30000M -22.40000M 5.60M 3.30M -5.10000M
Stock based compensation 6.00M 3.70M 7.70M 5.80M 3.00M
Other non cash items 21.10M -22.70000M 5.00M 4.60M 30.80M
Free cash flow 15.20M -16.60000M 33.70M 30.40M 5.10M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (GBP) Price (GBP) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
GNS
Genus PLC
-42.0 2.49% 1644.00 42.59 25.71 2.08 2.46 2.31 16.39
ONT
Oxford Nanopore Technologies Ltd
0.40 0.33% 122.80 - - 10.88 2.75 8.77 -16.7946
PRTC
PureTech Health plc
0.20 0.12% 162.00 - - 35.55 1.04 95.87 -4.5333
AVCT
Avacta Group PLC
2.25 5.08% 46.50 - - 23.19 14.78 20.75 -10.4566
BVXP
Bioventix
-40.0 1.07% 3710.00 27.22 25.97 18.06 18.93 17.37 21.69

Reports Covered

Stock Research & News

Profile

Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It sells breeding pigs and semen to breed pigs with various characteristics for pork production under the PIC brand. The company also sells bull semen and embryos to breed calves with various characteristics for milk and beef production under the ABS, Genus, and Bovec brands. In addition, it offers technical services to farmers. The company was incorporated in 1994 and is based in Basingstoke, the United Kingdom.

Genus PLC

Matrix House, Basingstoke, United Kingdom, RG21 4DZ

Key Executives

Name Title Year Born
Mr. Stephen Wilson CEO & Exec. Director 1960
Ms. Alison Henriksen CFO & Exec. Director 1967
Dr. William Christianson Chief Operating Officer NA
Dr. Elena Rice Head of R&D and Chief Scientific Officer NA
Mr. Dan Hartley Group Gen. Counsel & Company Sec. NA
Ms. Angelle R. Rosata Group HR Director NA
Mr. Jerry Thompson Chief Operating Officer of Genus ABS Beef NA
Dr. Nate Zwald Chief Operating Officer of Genus ABS Dairy NA
Ms. Janet Duane Group Financial Controller NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions